## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

AN 0 9 7004 (Use as many sheets as necessary)

RADEVA

Page 1 of 4

Application Number	10/675,833
Filing Date	September 30, 2003
First Named Inventor	Leslie J. Charles
Art Unit	Unknown
Examiner Name	Unknown
Attorney Case Number	57072US037

			U.S. Patent	Documents	
Exam Init.*	. Cite No.	Document Number  Doc. Number-(Kind Code if Known)	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BU	- A1	US- 3,314,941	04-18-1967	Littell et al.	
1	A2	US- 4,689,338	08-25-1987	John F. Gerster	
	A3	US- 4,698,348	10-06-1987	John F. Gerster	
	A4	US- 4,929,624	05-29-1990	Gerster et al.	
	A5	US- 4,988,815	01-29-1991	Andre et al.	
	A6	US- 5,037,986	08-06-1991	John F. Gerster	
	A7	US- 5,175,296	12-29-1992	Gerster	
	A8	US- 5,238,944	08-24-1993	Wick et al.	
	A9	US- 5,266,575	11-30-1993	John F. Gerster	
	A10	US- 5,268,376	12-07-1993	John F. Gerster	
	A11	US- 5,346,905	09-13-1994	John F. Gerster	
	A12	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A13	US- 5,367,076	11-22-1994	Gerster	
	A14	US- 5,389,640	02-14-1995	Gerster et al.	
	A15	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A16	US- 5,446,153	08-29-1995	Lindstrom et al.	•
	A17	US- 5,482,936	01-09-1996	Kyle J. Lindstrom	
	A18	US- 5,693,811	12-02-1997	Lindstrom	
	A19	US- 5,741,908	04-21-1998	Gerster et al.	
	A20	US- 5,756,747	05-26-1998	Gerster et al.	
	A21	US- 5,939,090	08-17-1999	Beaurline et al.	
	A22	US- 6,039,969	03-21-2000	Tomai et al.	
	A23	US- 6,069,149	05-30-2000	Nanba et al.	
	A24	US- 6,083,505	07-04-2000	Miller et al.	
	A25	US- 6,110,929	08-29-2000	Gerster et al.	
	A26	US- 6,194,425	02-27-2001	Gerster et al.	
	A27	US- 6,245,776	06-12-2002	Skwierczynski et al.	
SH	A28	US- 6,331,539	12-18-2001	Crooks et al.	

*Examiner: L. Huang	Date Considered: 4/29/04
EXAMINER: Initial if reference considered, whether or not citation conformance and not considered. Include copy of this form with ne	is in conformance with MPEP 609. Draw line through citation if not in ext communication to applicant.

## STATEMENT BY APPLICANT

JAN 0 9 2004 Use as many sheets as necessary)
Page 2 of 4

Applicati n Number	10/675,833
Filing Date	September 30, 2003
First Named Inventor	Leslie J. Charles
Art Unit	Unknown
Examiner Name	Unknown
Attorney Case Number	57072US037

			U.S. Patent	Documents		
Exam.	Cite	Document Number	Publication Date or Issue Date	Name of Patentee	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Init.*	No.	Doc. Number-(Kind Code if Known)	MM-DD-YYYY	or Applicant of Cited Document	Figures Appear	
St	A29	US- 6,376,669	04-23-2002	Rice et al.		
	A30	US- 2002/0055517 A1	05-09-2002	Smith		
	A31	US- 2002/0058674 A1	05-16-2002	Hedenstrom et al.		
	A32	US- 6,451,810	09-17-2002	Coleman et al.		
	A33	US- 6,518,265	02-11-2003	Kato et al.		
	A34	US- 6,525,064	02-25-2003	Dellaria et al.		
	A35	US- 6,541,485	04-01-2003	Crooks et al.		
	A36	US- 6,545,016	04-08-2003	Dellaria et al.		
	A37	US- 6,545,017	04-08-2003	Dellaria et al.		
	A38	US- 6,558,951	05-06-2003	Tomai et al.		
	A39	US- 6,573,273	06-03-2003	Crooks et al		
	A40	US- 6,656,938	12-02-2003	Crooks et al.		
	A41	US- 6,660,735	12-09-2003	Crooks et al.		
	A42	US- 6,664,264	12-16-2003	Dellaria et al.		
	A43	US- 6,664,265	12-16-2003	Crooks et al.		
SH	A44	US- 6,667,312	12-23-2003	Bonk et al.		

	Foreign Patent Documents						
Exam.	Cite	For	eign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	Translation
Init.*	No.	Ctry. Code	Number-KindCode (If known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	(Check if yes)
SH	B1	PCT	WO 01/74343	10-11-2001			
	B2	PCT	WO 02/36592	05-10-2002			х
	В3	PCT	WO 02/46188	06-13-2002			
	B4	PCT	WO 02/46189	06-13-2002			
	B5	PCT	WO 02/46190	06-13-2002			
	В6	PCT	WO 02/46193	06-13-2002			
	В7	PCT	WO 02/46749	06-13-2002			
	B8	PCT	WO 02/102377	12-27-2002			
\$A1	B9	PCT	WO 03/020889	03-13-2003			

*Examiner: & throng	Date Considered: 4/28/04
EXAMINER: Initial if reference considered, whether or not citation conformance and not considered. Include copy of this form with no	is in conformance with MPEP 609. Draw line through citation if not in ext communication to applicant.

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

JAN 0 9 2014 many sheets as necessary)

Page 3 of 4

Applicati n Number	10/675,833
Filing Date	September 30, 2003
First Named Inventor	Leslie J. Charles
Art Unit	Unknown
Examiner Name	Unknown
Attorney Case Number	57072US037

	Foreign Patent Documents						
Exam.	Cite	For	eign Patent Document	Publication Date	Publication Date Name of Patentee or	Pages, Columns, Lines,	Translation
Init.*	No.	Ctry. Code	Number-KindCode (If known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	(Check if yes)
SH	B10	PCT	WO 03/043572	05-30-2003			·
	B11	PCT	WO 03/045391	06-05-2003			
	B12	JP	9-208584	08-12-1997			
	B13	JP	9-255926	03-26-1999			X
	B14	JP	11-222432	08-17-1999			X
	B15	JP	2000-247884 (abs)	09-12-2000			X
	B16	EP	0 394 026	10-24-1990			
8/41	B17	EP	1 104 764	06-06-2001			

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
8at	C1	Wozniak, et al, "The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate <sup>1,2</sup> . A New and Convenient Amination Method.", <u>Journal of the Royal Netherlands Chemical Society</u> , 102, pp 511-513, December 12, 1983.				
-	C2	Brennan, et al, "Automated Bioassay of Interferons in Micro-test Plates", <u>Biotechniques</u> , June/July, 78, 1983.				
	C3	Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, Volume 58, pp. 365-372, September 1995.				
	C4	Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline", J. Org. Chem, 15, pp 1278-1284 (1950).				
	C5	Jain, et al, "Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines", J. Med. Chem., 11, pp 87-92 (1968).				
	C6	Baranov, et al., <u>Chem. Abs.</u> 85, 94362, (1976).				
	C7	Berényi, et al, "Ring Transformation of Condensed Dihydro-as-triazines", <u>J. Heterocyclic Chem.</u> , 18, pp 1537-1540 (1981).				
	C8	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical Development and Technology, 4(1), pp 35-43 (1999)				
	C9	Izumi, et al., "1 <i>H</i> -Imidazo[4,5- <i>c</i> ]quinoline Derivatives as Novel Potent TNF-α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]pyridines", Bioorganic & Medicinal Chemistry, 11, pp 2541-2550 (2003)				
SH	C10	Sidky etal., "Inhibition of Murine Tumor Growth by an Interferon-inducing Imidazoquinolinamine", Cancer Research, 52, 3528-3533, July 1, 1992.				

*Examiner: Le though	Date Considered: 4/38/0 4	
EXAMINER: Initial if reference considered, whether or not citation is conformance and not considered. Include copy of this form with ne	is in conformance with MPEP 609. Draw line through citation if not in ext communication to applicant,	•

## INFORMATION DISCLOSURE

AN 0 9 2004 (L

as many sheets as necessary)

Page 4 of 4

10/675,833
Sept mber 30, 2003
Leslie J. Charles
Unknown
Unknown
57072US037

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
810	R.L. Miller et al., "Imiquimod applied topically: a novel immune response modifier and new classification," International Journal of Immunopharmacology, 21, 1-14 (1999).					
	C12	Karl R. Beutner, MD, et al., "Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream", <u>J.Am.Acad.Dermatol.</u> , Volume 41, Number 6, 1002-1007 (December 1999).				
	C13	Davis et al., "Self-Administered Topical Imiquimod Treatment of Vulvar Intraepithelial Neoplasia", Journal of Reproductive Medicine, Volume 45, Number 8, 619-623, (August 2000).				
8H	C14	Alexander Steinmann et al., "Topical Imiquimod Treatment of a Cutaneous Melanoma Metastasis", J.Am.Acad.Dermatol., Letters, 555-556 (September 2000).				

Examiner:	offung.	Date C nsidered:	4/28/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.